Indications for Enfortumab

Enfortumab is a new type of targeted therapy drug suitable for the treatment of advanced or metastatic urothelial cancer (urothelial cancer). Urothelial carcinoma is a malignant tumor that usually originates from the epithelial cells of the urinary system, including the bladder, urethra, renal pelvis, and ureters. Urothelial carcinoma often metastasizes at an advanced stage, affecting patients' quality of life and prognosis. Therefore, it is particularly important to find effective treatment options.

The indications for ennosumab are mainly for patients with advanced or metastatic urothelial carcinoma, especially those who have previously received platinum-based chemotherapy andPD-1/PD-L1 inhibitors but whose disease still progresses. These patients often respond poorly to or develop resistance to traditional treatment regimens, so new treatment strategies are needed to improve treatment efficacy and survival rates.

Ennosumab binds to the Nectin-4 target, releases cytotoxins, triggers apoptosis of cancer cells, thereby blocking the growth and spread of cancer cells. Nectin-4 is a protein overexpressed in a variety of cancers, including urothelial cancer. Under the action of ennosumab, it can selectively kill Nectin-4 positive cancer cells and reduce damage to healthy tissue, thereby achieving the purpose of treatment.

In general, ennosumab, as a new type of targeted therapy, is suitable for the treatment of patients with advanced or metastatic urothelial cancer, especially for patients who have previously received platinum-based chemotherapy andPD-1/PD-L1 inhibitors but whose disease still progresses. Its launch provides a new treatment option for this patient group and brings new hope for improving the treatment effect and prognosis of urothelial cancer.